Tag: Covaxin

COVID19 Vaccine: Covaxin Price Fixed At Rs 600 For States, Rs 1,200 For Pvt Hospitals
COVID19 Vaccine: Covaxin Price Fixed At Rs 600 For States, Rs 1,200 For Pvt Hospitals

New Delhi: Bharat Biotech on Saturday said it would provide its COVID-19 vaccine, Covaxin, to state governments at Rs 600 per dosage. The Hyderabad-based vaccine major also said that it would…

  • Saturday, 24 April 2021
Coronavirus
Faster Jabs, Surveillance Can Only Tame Triple-Mutant Indian Virus

New Delhi: Increasing efforts towards faster mass vaccination and virus surveillance is the key to ward off dangers posed by a triple-mutant coronavirus now present in the country, health experts…

  • Wednesday, 21 April 2021
COVAXIN
Covaxin Neutralises Double Mutant Strain: ICMR

New Delhi: Indigenously developed COVID-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said…

  • Wednesday, 21 April 2021
COVID19 Vaccine: Govt Waives Import Duty On Remdesivir, Its APIs
COVID19 Vaccine: Govt Waives Import Duty On Remdesivir, Its APIs

New Delhi: Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug.…

  • Tuesday, 20 April 2021
Covaxin Production To Increase 10 Times By September: Union Health Minister
Covaxin Production To Increase 10 Times By September: Union Health Minister

New Delhi: Union Health Minister Harsh Vardhan on Sunday said there will be a 10 times rise in Covaxin vaccine production by September while manufacture of remdesivir jabs, an anti-viral…

  • Sunday, 18 April 2021
Covaxin
COVAXIN-India’s 1st COVID-19 Vaccine Candidate Gets DCGI Nod For Human Trials

Hyderabad: Bharat Biotech, has successfully developed COVAXIN, India’s 1st vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level […]

  • Thursday, 15 April 2021
Zydus-Cadila
COVID-19 Vaccine: Zydus Cadila Gets DCGI Nod For Human Clinical Trials

New Delhi: After Bharat Biotech’s Covaxin, another potential COVID-19 vaccine indigenously developed by Ahmedabad-based Zydus Cadila Healthcare Ltd got nod from the Drugs Controller General of India (DCGI) on Thursday for human clinical trials, government sources said. The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency […]

  • Thursday, 15 April 2021
Covaxin
ICMR Fast-tracks 'Covaxin', Intend Launch By August 15

New Delhi: The Indian Council of Medical Research (ICMR) said that it has partnered with Bharat Biotech to fast-track clinical trials of  India’s first indigenous COVID-19 vaccine Covaxin. ICMR Director General Balram Bhargava asserted that ICMR aims to launch the indigenous COVID-19 vaccine by August 15 after its completion of the clinical trials. In a […]

  • Thursday, 15 April 2021
covaxin
COVID-19 Vaccine: India Sounds Confident Of Covaxin

New Delhi: As India races to bring a vaccine for Covid-19 by mid-August, the government on Sunday said that it is entering the human trial stage which “marks the beginning of the end”. COVAXIN by Bharat Biotech and ZyCov-D vaccine by Zydus Cadila is India’s own efforts to bring a vaccine for this global pandemic. […]

  • Thursday, 15 April 2021
COVAXIN
COVID-19 Vaccine - No Vaccine In India Before 2021, Officials Tell Parliament Panel

New Delhi: As soon as the Parliamentary standing committees started to resume work after a long spell of hibernation, it was not all good news that came in front of them. Notwithstanding the ambitious target set for its market launch, the Standing Committee on Science and Technology was told on Friday that India will have […]

  • Thursday, 15 April 2021
Covaxin
COVID Vaccine: Bharat Biotech Begins Human Trial Of Covaxin In India

Chandigarh: The human trial of Bharat Biotech’s anti-COVID-19 vaccine Covaxin began at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij tweeted. In his tweet, the minister also said the vaccine has been administered to three persons who have shown no adverse effect to it. “Human trial with Corona vaccine (COVAXIN) […]

  • Thursday, 15 April 2021
Covaxin's Phase-3 Trials Begin: Bharat Biotech
AIIMS To Begin COVID Vaccine Human Trial From Next Week

New Delhi: In a major development, AIIMS Delhi will begin human trials of India’s first indigenous Covid-19 vaccine, Covaxin, from next week on 100 healthy volunteers aged between 18 and 55. The volunteers will be kept under observation for a period of nearly 150 days. Covaxin is developed by Bharat Biotech in collaboration with the […]

  • Wednesday, 14 April 2021
COVID19 Vaccine in India
Seven Indian Pharma Players Race To Develop COVID-19 Vaccine

New Delhi: At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already infected more than 14 million globally. Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological […]

  • Wednesday, 14 April 2021
Covaxin-clinical Trail
Clinical Trials Of COVID Vaccine Set To Start In Bhubaneswar From Wednesday

Bhubaneswar: Human clinical trials of the country’s indigenously developed COVID-19 vaccine is set to begin this week at a Bhubaneswar-based institute — one of the 12 centres selected by the ICMR for conducting phase one and two of the process, a senior official said. The human trials of BBV152 COVID Vaccine or Covaxin will begin […]

  • Wednesday, 14 April 2021
Covaxin's Phase-3 Trials Begin: Bharat Biotech
COVID-19 Vaccine: Animal Study Proved Vax's Efficacy, Says Bharat Biotech

Hyderabad: Vaccine maker Bharat Biotech on Friday announced that the animal trials of its Covid-19 vaccine candidate Covaxin were successful. It said the results demonstrated the protective efficacy of the vaccine in a live viral challenge model. “Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in […]

  • Monday, 12 April 2021
scrollToTop